Skip to main content
. Author manuscript; available in PMC: 2009 Aug 11.
Published in final edited form as: J Neurosci. 2009 Feb 11;29(6):1615–1625. doi: 10.1523/JNEUROSCI.2081-08.2009

Figure 6. Spontaneous Synchronous Ethosuximide-Sensitive Spike-Wave Seizures in α1G Transgenic Mice.

Figure 6

Representative bilateral cortical EEG recordings (L, left; R, right) of freely moving WT, α1G-Tg1, and α1G-Tg2 mice demonstrating that both the α1G-Tg1 and α1G-Tg2 mice develop spike-wave seizures, while WT mice show normal EEG activity. Administration of the anti-epileptic drug ethosuximide (ETX) suppresses the spike-wave seizures produced in both the α1G-Tg1 and α1G-Tg2 mice. Comparison of the average number of observed spike-wave seizures per hour reveals an increased incidence in the α1G-Tg2 line (25.8 ± 4.9; ranging from 5-55 seizures/hour; 12 hours from 4 mice) over the α1G-Tg1 line (11.0 ± 2.4; ranging from 1-45 seizures/hour; 23 hours from 4 mice). Comparisons of individual spike-wave discharge frequency and duration show no significant differences between the α1G-Tg1 (16 seizures from 6 mice) and α1G-Tg2 (16 seizures from 5 mice) lines.